Enkelejda Plasa, MD
Internal Medicine · Westlake, OHNPI 1912988171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,608, 2.9 times the $555 reported in 2019.
Across 207 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$638
- AbbVie$427
- Novo Nordisk$287
- Lilly USA, LLC$277
- GSK$252
- Pfizer$225
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,500100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $638 |
| AbbVie(2 entities) | 24 | $427 |
| Novo Nordisk | 18 | $287 |
| Lilly USA, LLC | 18 | $277 |
| GSK | 16 | $252 |
| Pfizer | 17 | $225 |
| Amgen | 10 | $186 |
| Kowa Pharmaceuticals America, Inc. | 11 | $176 |
| Johnson & Johnson | 9 | $167 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| Astellas Pharma US Inc | 5 | $96 |
| Boehringer Ingelheim | 3 | $61 |
| Exact Sciences | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| TMS Neurohealth Centers Inc. | 3 | $52 |
| Pacira Pharmaceuticals Incorporated | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Abbott | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Currax Pharmaceuticals LLC | 2 | $34 |
| Dexcom, Inc. | 2 | $32 |
| Bayer | 2 | $32 |
| Novartis | 2 | $26 |
| Merck | 2 | $24 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $13 |
How this compares
$3,500 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $143,788 |
| OzempicSemaglutide | 105 | $134,108 |
| JardianceEmpagliflozin | 89 | $82,997 |
| JanuviaSitagliptin Phosphate | 54 | $52,820 |
| XareltoRivaroxaban | 37 | $49,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $34,960 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $13,209 |
| MounjaroTirzepatide | 11 | $13,200 |
| EntrestoSacubitril/Valsartan | 12 | $11,835 |
| LinzessLinaclotide | 12 | $11,217 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,774 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $9,712 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $8,041 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $6,832 |
| Levothyroxine Sodium | 489 | $6,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $225 | $148,059162 claims |
| Novo NordiskOzempic | $287 | $134,108105 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $61 | $96,206111 claims |
| MerckJanuvia | $24 | $52,82054 claims |
| Johnson & JohnsonXarelto | $167 | $49,87337 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $252 | $44,73449 claims |
| AbbVieLinzess, Synthroid | $427 | $13,62481 claims |
| Lilly USA, LLCMounjaro | $277 | $13,20011 claims |
| NovartisEntresto | $26 | $11,83512 claims |
| AstraZenecaSymbicort | $638 | $9,71222 claims |
| Astellas Pharma US IncMyrbetriq | $96 | $5,65712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Westlake
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.